Alzheimer's failure spawns 130 job cuts at J&J

A doomed Alzheimer's program has triggered layoffs. Johnson & Johnson ($JNJ) is making deep cuts in an Alzheimer's immunotherapy unit in the aftermath of a colossal Phase III failure of a program to advance bapineuzumab against the memory-stealing disease. Report

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.